These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

690 related items for PubMed ID: 23885145

  • 1. Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn's disease and rheumatoid arthritis: results of a systematic review.
    Fidder HH, Singendonk MM, van der Have M, Oldenburg B, van Oijen MG.
    World J Gastroenterol; 2013 Jul 21; 19(27):4344-50. PubMed ID: 23885145
    [Abstract] [Full Text] [Related]

  • 2. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    van Herwaarden N, den Broeder AA, Jacobs W, van der Maas A, Bijlsma JW, van Vollenhoven RF, van den Bemt BJ.
    Cochrane Database Syst Rev; 2014 Sep 29; (9):CD010455. PubMed ID: 25264908
    [Abstract] [Full Text] [Related]

  • 3. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.
    Oladapo A, Barner JC, Lawson KA, Novak S, Rascati KL, Richards KM, Harrison DJ.
    J Manag Care Spec Pharm; 2014 Jul 29; 20(7):657-67. PubMed ID: 24967519
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA, Klingman D, Hazard E, Ray S.
    Clin Ther; 2009 Apr 29; 31(4):825-35. PubMed ID: 19446156
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naïve rheumatoid arthritis patients in US health plans.
    Joyce AT, Gandra SR, Fox KM, Smith TW, Pill MW.
    J Med Econ; 2014 Jan 29; 17(1):1-10. PubMed ID: 24131136
    [Abstract] [Full Text] [Related]

  • 9. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.
    Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K, Connock M, Jobanputra P, Moore D, Fry-Smith A, Chen YF.
    Health Technol Assess; 2011 Mar 29; 15(14):1-278. PubMed ID: 21439251
    [Abstract] [Full Text] [Related]

  • 10. Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice.
    Moots RJ, Haraoui B, Matucci-Cerinic M, van Riel PL, Kekow J, Schaeverbeke T, Davis A, Tedeschi MA, Freundlich B, Chang DJ, Singh A.
    Clin Exp Rheumatol; 2011 Mar 29; 29(1):26-34. PubMed ID: 21345289
    [Abstract] [Full Text] [Related]

  • 11. Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-alpha antagonists.
    Curtis JR, Kramer JM, Martin C, Saag KG, Patkar N, Shatin D, Burgess M, Xie A, Braun MM.
    Rheumatology (Oxford); 2007 Nov 29; 46(11):1688-93. PubMed ID: 17938138
    [Abstract] [Full Text] [Related]

  • 12. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab.
    Neovius M, Arkema EV, Olsson H, Eriksson JK, Kristensen LE, Simard JF, Askling J, ARTIS Study Group.
    Ann Rheum Dis; 2015 Feb 29; 74(2):354-60. PubMed ID: 24285495
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy of treatment intensification with adalimumab, etanercept and infliximab in rheumatoid arthritis: a systematic review of cohort studies with focus on dose.
    Eng G, Stoltenberg MB, Szkudlarek M, Bouchelouche PN, Christensen R, Bliddal H, Marie Bartels E.
    Semin Arthritis Rheum; 2013 Oct 29; 43(2):144-51. PubMed ID: 23838092
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A.
    JAMA; 2009 Feb 18; 301(7):737-44. PubMed ID: 19224750
    [Abstract] [Full Text] [Related]

  • 18. Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients.
    Zhang J, Xie F, Delzell E, Yun H, Lewis JD, Haynes K, Chen L, Beukelman T, Saag KG, Curtis JR.
    Arthritis Care Res (Hoboken); 2015 May 18; 67(5):624-32. PubMed ID: 25370912
    [Abstract] [Full Text] [Related]

  • 19. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
    Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, Kollerup G, Linde L, Lindegaard HM, Poulsen UE, Schlemmer A, Jensen DV, Jensen S, Hostenkamp G, Østergaard M, All Departments of Rheumatology in Denmark.
    Arthritis Rheum; 2010 Jan 18; 62(1):22-32. PubMed ID: 20039405
    [Abstract] [Full Text] [Related]

  • 20. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis.
    Doan QV, Chiou CF, Dubois RW.
    J Manag Care Pharm; 2006 Sep 18; 12(7):555-69. PubMed ID: 16981801
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.